Athira C Rajeev

Dr. Athira C Rajeev

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in DNA and Cell Biology
Verified
Journal Article
Closed access
ALAnjana C. Lalu
Anjana C. Lalu
FLFathimathul Lubaba
Fathimathul Lubaba
AGAthira Perunelly Gopalakrishnan
Athira Perunelly Gopalakrishnan
AMAlthaf Mahin
Althaf Mahin
SSSuhail Subair
Suhail Subair
RRRajesh Raju
Rajesh Raju
Bromodomain-containing protein 4 (BRD4) is a pivotal transcriptional regulator implicated in cancer, fibrosis, and inflammation, yet its phospho-regulatory network remains underexplored. This study leverages an extensive analysis of 1000 qualitative and 225 quantitative global phosphoproteome datasets to decode the BRD4 phosphorylation landscape. We identified S601 and S1117 as predominant phosphorylation sites, driving the majority of BRD4 phospho-signaling. Co-regulation analysis revealed 755 and 972 proteins positively cophosphorylated with S601 and S1117, respectively, including key interactors like TRIM28 (S473) and PRKAR2A (S78), which enhance transcriptional activity and cAMP signaling. Upstream kinases MAPK14 and GRK5 emerged as high-confidence regulators of S1117 and S601, respectively, with correlations in breast cancer highlighting disease relevance. In addition, 93 phosphosites in 71 transcription factors co-regulated with S1117 and 69 in 53 with S601 underscore the role of BRD4 in transcription control. These findings unveil a complex phospho-signaling network, offering novel therapeutic targets for BRD4-associated diseases and a foundation for future experimental validation.

6 January 2026 in Molecular Genetics and Genomics
Verified
Journal Article
Closed access
PDF file
APApoorva Pai
Apoorva Pai
AMAlthaf Mahin
Althaf Mahin
SUSamseera Ummar
Samseera Ummar
AGAthira Perunelly Gopalakrishnan
Athira Perunelly Gopalakrishnan
PSPrathik Basthikoppa Shivamurthy
Prathik Basthikoppa Shivamurthy
RRRajesh Raju
Rajesh Raju

19 January 2026 in Journal of Molecular Evolution
Verified
Journal Article
Closed access
PDF file
NKNoreen A Khan
Noreen A Khan
ARAthira C Rajeev
Athira C Rajeev
AMAlthaf Mahin
Althaf Mahin
AGAthira Perunelly Gopalakrishnan
Athira Perunelly Gopalakrishnan
PSPrathik Basthikoppa Shivamurthy
Prathik Basthikoppa Shivamurthy
RRRajesh Raju
Rajesh Raju

8 May 2026 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
NKNoreen A Khan
Noreen A Khan
AFAmal Fahma
Amal Fahma
AMAlthaf Mahin
Althaf Mahin
AGAthira Perunelly Gopalakrishnan
Athira Perunelly Gopalakrishnan
PSPrathik Basthikoppa Shivamurthy
Prathik Basthikoppa Shivamurthy
RRRajesh Raju
Rajesh Raju
Maternal embryonic leucine zipper kinase (MELK) is a serine/threonine kinase frequently overexpressed in aggressive cancers, yet the precise mechanisms governing its activation and signaling specificity remain poorly understood. Here, we present the first phosphosite-resolved co-regulation atlas of MELK through integrative meta-analysis of 3,825 global human phosphoproteomics datasets. Three phosphosites-S356, S505, and S529-emerge as dominant regulatory nodes, exhibiting high detection frequency and distinct co-regulation patterns. S356 and S505 form a tightly coupled proliferative-mitotic axis controlled by convergent Mitogen-Activated Protein Kinase Kinase (MAPK), Ribosomal S6 Kinase (RSK), Calcium/Calmodulin-dependent protein Kinase (CaMK), Hippo-related, and spindle-checkpoint kinases (NIMA-related kinase 4 (NEK4), Threonine Tyrosine Kinase/Monopolar Spindle 1 Kinase (TTK/MPS1)), whereas S529 functions as a partially antagonistic stress- and polarity-responsive module. Marker of Proliferation Ki-67 (MKI67) phosphosites co-vary with all three MELK sites across virtually all proliferative contexts, establishing a direct mechanistic link between MELK activity and clinical proliferation markers. Extensive networks of co-regulated upstream kinases, phosphatases, binary interactors, and downstream substrates further reveal functional segregation: S356/S505 primarily drive cell-cycle progression and chromatin organization, while S529 integrates calcium, metabolic, and cytoskeletal polarity signals. Kaplan-Meier survival analysis across TCGA cohorts further revealed that high expression of MELK, MKI67, and the mitotic checkpoint kinase TTK consistently predicts poor overall and disease-free survival in lung adenocarcinoma and hepatocellular carcinoma, reinforcing the strong phosphodynamic coupling between MELK activity and clinical proliferation markers. By demonstrating that MELK signaling is orchestrated through modular, site-specific phosphorylation logic rather than total protein abundance, this work establishes a new paradigm for understanding and therapeutically targeting this enigmatic oncogenic kinase.

Verified
Journal Article
Open access
PDF file
JVJishna Vijayan
Jishna Vijayan
SSSuhail Subair
Suhail Subair
MAMukhtar Ahmed
Mukhtar Ahmed
AGAthira P G
Athira P G
ASAlimath Sambreena
Alimath Sambreena
ARAthira C Rajeev
Athira C Rajeev
Tousled-like kinases 1 and 2 (TLK1 and TLK2) are paralogous serine/threonine kinases that share high sequence similarity yet exhibit functional divergence in cellular processes such as DNA replication, damage response, and chromatin organization. This study elucidates the paralog-specific co-phosphoregulatory networks underlying this divergence through a comprehensive analysis of 3825 human phosphoproteomic articles. Predominant phosphosites were identified as S134 and T38 for TLK1 and S73, S99, and S111 for TLK2, revealing context-dependent regulation across cancers and perturbations. Co-phosphoregulation analyses uncovered distinct networks: TLK1 associates with DNA damage signaling via proteins like ABRAXAS1, PML, and RAD9A, while TLK2 integrates with chromatin remodeling and replication through CHD4, DOT1L, NASP, and RNF20. Upstream kinases for TLK2, predominantly CDKs, link it to cell-cycle progression, whereas downstream substrates and binary interactors converge on genome stability pathways with paralog-specific nuances. These findings highlight the potential role of TLK1 on checkpoint activation and TLK2 on replication-coupled chromatin maintenance, providing insights into their roles in cancer amplification and therapeutic resistance, as well as neurodevelopmental disorders, where emerging evidence also support the involvement of TLK1 alongside TLK2.

1 October 2026 in Amino Acids
Verified
Journal Article
Open access
PDF file
JVJishna Vijayan
Jishna Vijayan
SSSuhail Subair
Suhail Subair
MAMukhtar Ahmed
Mukhtar Ahmed
AGAthira Perunelly Gopalakrishnan
Athira Perunelly Gopalakrishnan
LJLevin John
Levin John
RRRajesh Raju
Rajesh Raju
Myeloid/Lymphoid or Mixed-Lineage Leukemia Translocated to 1 (MLLT1), also known as ENL, is a critical chromatin-associated protein within the super elongation complex (SEC) that regulates transcriptional elongation and is frequently implicated in leukemias and Wilms tumor through fusions and mutations. Despite its oncogenic roles, the phosphoregulatory mechanisms of MLLT1 remain underexplored. This study integrates large-scale phosphoproteomic datasets to identify predominant phosphosites (S292, S359, S361) on MLLT1 and delineate their co-phosphoregulated protein networks using Fisher’s Exact Test, Gene Ontology enrichment, and interaction databases. Results reveal a network enriched in chromatin remodeling, histone binding, transcription elongation via SEC and PAF complexes, RNA processing, and genome stability, with S292 emerging as a significant phosphorylation site. Upstream kinases, such as CDK9, and binary interactors, including KMT2A and DOT1L, underscore MLLT1’s integration of phosphorylation with epigenetic control. Cancer associations link these phosphosites to leukemia, Wilms tumor, and potentially lung cancers, highlighting novel therapeutic avenues. This analysis provides mechanistic insights into MLLT1’s phosphoregulated functions in transcriptional control and oncogenesis.